Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’

IF 81.1 1区 医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-10-25 DOI:10.1038/s41571-024-00953-4
Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna
{"title":"Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’","authors":"Christopher Nevala-Plagemann, Thierry Conroy, Ignacio Garrido-Laguna","doi":"10.1038/s41571-024-00953-4","DOIUrl":null,"url":null,"abstract":"<p>We appreciate the interest of Wainberg and O’Reilly in our recently published News &amp; Views article that critiques the design and reporting of results from the NAPOLI 3 trial (Nevala-Plagemann, C. &amp; Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? <i>Nat. Rev. Clin. Oncol</i>. <b>21</b>, 567–568 (2024))<sup>1</sup>. In their Correspondence (Wainberg, Z. A. &amp; O’Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. <i>Nat. Rev. Clin. Oncol</i>. https://doi.org/10.1038/s41571-024-00952-5 (2024))<sup>2</sup>, they raise several points that we would like to address.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00953-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We appreciate the interest of Wainberg and O’Reilly in our recently published News & Views article that critiques the design and reporting of results from the NAPOLI 3 trial (Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev. Clin. Oncol. 21, 567–568 (2024))1. In their Correspondence (Wainberg, Z. A. & O’Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/s41571-024-00952-5 (2024))2, they raise several points that we would like to address.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
回复 "NALIRIFOX在转移性胰腺癌一线治疗中的应用:NAPOLI 3以外的证据
我们感谢 Wainberg 和 O'Reilly 对我们最近发表的《新闻与观点》(News & Views)一文的关注,该文批评了 NAPOLI 3 试验的设计和结果报告(Nevala-Plagemann, C. & Garrido-Laguna, I. NALIRIFOX 治疗转移性胰腺腺癌:希望还是炒作?Nat.Rev. Clin.Oncol.21, 567-568 (2024))1.在他们的通信(Wainberg, Z. A. & O'Reilly, E. M. NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3. Nat.Rev. Clin.https://doi.org/10.1038/s41571-024-00952-5 (2024))2,他们提出了几点我们希望解决的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
期刊最新文献
Cadonilimab is effective and safe in recurrent cervical cancer NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3 Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’ Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer The TOPGEAR trial — is chemoradiotherapy no longer a component of multidisciplinary care for gastric cancer?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1